A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study aims to analyze the efficacy and safety of passive immunotherapy by administering
an equine hyperimmune serum (INM005) against the SARS-CoV2 RBD to Covid19 patients.
Improvement of the clinical course 28 days after the start of treatment will be evaluated.